{"id":394130,"date":"2020-12-07T07:38:08","date_gmt":"2020-12-07T12:38:08","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=394130"},"modified":"2020-12-07T07:38:08","modified_gmt":"2020-12-07T12:38:08","slug":"infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/","title":{"rendered":"Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwuline { text-decoration: underline }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium<\/b><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.infi.com%2F&amp;esheet=52343547&amp;newsitemid=20201207005253&amp;lan=en-US&amp;anchor=Infinity+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=7e6880ca85c5fab3162e4bf72b3caec4\">Infinity Pharmaceuticals, Inc.<\/a> (NASDAQ: INFI) will hold a conference call on Wednesday, December 9, 2020 at 10:00 a.m. ET to discuss clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) which will be presented during the San Antonio Breast Cancer Symposium (SABCS) being held virtually, December 8-11, 2020.\n<\/p>\n<p><b>Conference Call Information<\/b><\/p>\n<p>\nA live webcast of the conference call can be accessed in the &#8220;Investors\/Media&#8221; section of Infinity&#8217;s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.infi.com%2F&amp;esheet=52343547&amp;newsitemid=20201207005253&amp;lan=en-US&amp;anchor=www.infi.com&amp;index=2&amp;md5=ee2d22d914e1960fb6b653d5bd55d061\">www.infi.com<\/a>. To participate in the conference call, please dial (877) 316-5293 (domestic) and (631) 291-4526 (international) five minutes prior to start time. The conference ID number is 2088322. An archived version of the webcast will be available on Infinity&#8217;s website for 30 days.\n<\/p>\n<p><b><span class=\"bwuline\">Presentation Details:<\/span><\/b><\/p>\n<p><b>Title:<\/b> MARIO-3 phase II study initial data evaluating a novel triplet combination of eganelisib (IPI-549), atezolizumab (atezo), and nab-paclitaxel (nab-pac) as first-line (1L) therapy for locally advanced or metastatic triple-negative breast cancer (TNBC)\n<\/p>\n<p><b>Presenter: <\/b>Erika Hamilton, M.D., Tennessee Oncology\n<\/p>\n<p><b>Date:<\/b> Wednesday, December 9, 2020, 8:00 a.m. CT\n<\/p>\n<p><b>Abstract:<\/b> PS11-32\n<\/p>\n<p><b>Poster Session:<\/b> 11\n<\/p>\n<p><b>Title:<\/b> ARC-2: Efficacy and safety of etrumadenant (AB928) + pegylated liposomal doxorubicin (PLD) \u00b1 eganelisib (IPI-549) in participants with metastatic ovarian and triple negative breast cancer\n<\/p>\n<p><b>Date:<\/b> Wednesday, December 9, 2020, 8:00 a.m. CT\n<\/p>\n<p><b>Abstract:<\/b> PS12-12\n<\/p>\n<p><b>Poster Session:<\/b> 12\n<\/p>\n<p><b>About Infinity and Eganelisib <\/b><\/p>\n<p>\nInfinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, controlled combination study of eganelisib combined with Opdivo<sup>\u00ae<\/sup> in I\/O na\u00efve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq<sup>\u00ae<\/sup> and Abraxane<sup>\u00ae<\/sup> in front-line TNBC and in combination with Tecentriq and Avastin<sup>\u00ae<\/sup> in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus AB928 (dual adenosine receptor antagonist) plus Doxil<sup>\u00ae<\/sup> in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1\/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I\/O-na\u00efve, and front-line settings. For more information on Infinity, please refer to Infinity&#8217;s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.infi.com%2F&amp;esheet=52343547&amp;newsitemid=20201207005253&amp;lan=en-US&amp;anchor=www.infi.com&amp;index=3&amp;md5=d211059bd1e0953dcdd2e0ce4ce3fcde\">www.infi.com<\/a>.\n<\/p>\n<p>\nOpdivo<sup>\u00ae<\/sup> is a registered trademark of Bristol Myers Squibb.\n<\/p>\n<p>\nTecentriq\u00ae is a registered trademark of Genentech, Inc.\n<\/p>\n<p>\nAbraxane\u00ae is a registered trademark of Celgene.\n<\/p>\n<p>\nDoxil\u00ae is a registered trademark of Janssen Products.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201207005253r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201207005253\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201207005253\/en\/<\/a><\/span><\/p>\n<p>\nAshley Robinson<br \/>\n<br \/>LifeSci Advisors, LLC<br \/>\n<br \/>617-775-5956\n<\/p>\n<p><b>KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will hold a conference call on Wednesday, December 9, 2020 at 10:00 a.m. ET to discuss clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) which will be presented during the San Antonio Breast Cancer Symposium (SABCS) being held virtually, December 8-11, 2020. Conference Call Information A live webcast of the conference call can be accessed in the &#8220;Investors\/Media&#8221; section of Infinity&#8217;s website at www.infi.com. To participate in the conference call, please dial (877) 316-5293 (domestic) and (631) 291-4526 (international) five minutes prior to start time. The conference ID number is 2088322. An archived version of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-394130","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will hold a conference call on Wednesday, December 9, 2020 at 10:00 a.m. ET to discuss clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) which will be presented during the San Antonio Breast Cancer Symposium (SABCS) being held virtually, December 8-11, 2020. Conference Call Information A live webcast of the conference call can be accessed in the &#8220;Investors\/Media&#8221; section of Infinity&#8217;s website at www.infi.com. To participate in the conference call, please dial (877) 316-5293 (domestic) and (631) 291-4526 (international) five minutes prior to start time. The conference ID number is 2088322. An archived version of &hellip; Continue reading &quot;Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-07T12:38:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201207005253r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium\",\"datePublished\":\"2020-12-07T12:38:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\\\/\"},\"wordCount\":480,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201207005253r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\\\/\",\"name\":\"Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201207005253r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-07T12:38:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201207005253r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201207005253r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium - Market Newsdesk","og_description":"Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will hold a conference call on Wednesday, December 9, 2020 at 10:00 a.m. ET to discuss clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) which will be presented during the San Antonio Breast Cancer Symposium (SABCS) being held virtually, December 8-11, 2020. Conference Call Information A live webcast of the conference call can be accessed in the &#8220;Investors\/Media&#8221; section of Infinity&#8217;s website at www.infi.com. To participate in the conference call, please dial (877) 316-5293 (domestic) and (631) 291-4526 (international) five minutes prior to start time. The conference ID number is 2088322. An archived version of &hellip; Continue reading \"Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-07T12:38:08+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201207005253r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium","datePublished":"2020-12-07T12:38:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/"},"wordCount":480,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201207005253r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/","name":"Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201207005253r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-07T12:38:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201207005253r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201207005253r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-pharmaceuticals-announces-conference-call-for-the-2020-san-antonio-breast-cancer-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Infinity Pharmaceuticals Announces Conference Call for the 2020 San Antonio Breast Cancer Symposium"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/394130","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=394130"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/394130\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=394130"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=394130"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=394130"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}